Michael Balk, MD
Cardiovascular Disease · Atlanta, GANPI 1205820024
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,950 of the $7,711 with a category attached, or 64.2%. Philips North America LLC accounts for 70.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $5,451 and has fallen 98.1% since, to $103 in 2025.
Across 17 payments — averaging $453.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$5K
- Intuitive Surgical$2K
- Akcea Therapeutics, Inc.$120
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$119
- Heartflow, Inc.$103
- Kestra Medical Technology Services, Inc.$92
- plus $49 from 3 others
What the payments were for
- Consulting fees$4,95064%
- Speaking & faculty fees$6959%
- Travel & lodging$94612%
- Food & beverage$1,12115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 4 | $5,451 |
| Intuitive Surgical | 5 | $1,778 |
| Akcea Therapeutics, Inc. | 1 | $120 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $119 |
| Heartflow, Inc. | 1 | $103 |
| Kestra Medical Technology Services, Inc. | 1 | $92 |
| Cardiva Medical, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (2858) General Consulting$5,451
- Da Vinci Surgical System$1,751
- TEGSEDI$120
- FFRct$103
How this compares
$7,711 in reported general payments places this provider in the 80th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 257 | $303,534 |
| XareltoRivaroxaban | 71 | $99,958 |
| FarxigaDapagliflozin Propanediol | 22 | $19,252 |
| Repatha SureclickEvolocumab | 26 | $18,845 |
| EntrestoSacubitril/Valsartan | 12 | $16,129 |
| Nebivolol Hcl | 88 | $4,908 |
| Rosuvastatin Calcium | 347 | $2,943 |
| Metoprolol Succinate | 224 | $2,556 |
| Prasugrel Hcl | 17 | $2,296 |
| Flecainide Acetate | 30 | $1,612 |
| Atorvastatin Calcium | 179 | $1,365 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $1,088 |
| Bisoprolol Fumarate | 26 | $903 |
| Amlodipine Besylate | 172 | $885 |
| Losartan Potassium | 98 | $879 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Atlanta
- Joseph MillerAtlanta$573K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Mani VannanAtlanta$157K
- Victor CorriganAtlanta$114K
- Elizabeth OfiliAtlanta$107K
- Isida BykuAtlanta$78K
- Cindy GrinesAtlanta$75K
- Anekwe OnwuanyiAtlanta$56K
- Melvin EcholsAtlanta$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.